Biomedical subjects

Peter S Conti

Publications and source records attributed to Peter S Conti.

38 records · Page 3Linked to original sources

PubMedDate not supplied

Glucose metabolism of human prostate cancer mouse xenografts.

We hypothesized that the glucose metabolism of prostate cancer is modulated by androgen. We performed in vivo biodistribution and imaging studies of [F-18] fluorodeoxyglucose (FDG) accumulation in androgen-sensitive (CWR-22) and androgen-independent (PC-3) human prostate cancer xenografts implanted in castrated and noncastrated male athymic mice. The growth pattern of the CWR-22 tumor was best approximated by an exponential function (tumor size in mm3 = 14.913 e(0.1086 x days), R2 = .96, n = 5). The growth pattern of the PC-3 tumor was best approximated by a quadratic function (tumor size in mm3 = 0.3511 x days2 + 49.418 x day - 753.33, R2 = .96, n = 3). The FDG accumulation in the CWR-22 tumor implanted in the castrated mice was significantly lower, by an average of 55%, in comparison to that implanted in the noncastrated host (1.27 vs. 2.83, respectively, p < .05). The 3-week maximal standardized uptake value (SUVmax) was 0.99 +/- 0.43 (mean +/- SD) for CWR-22 and 1.21 +/- 0.32 for PC-3, respectively. The 5-week SUVmax was 1.22 +/- 0.08 for CWR-22 and 1.35 +/- 0.17 for PC-3, respectively. The background muscle SUVmax was 0.53 +/- 0.11. Glucose metabolism was higher in the PC-3 tumor than in the CWR-22 tumor at both the 3-week (by 18%) and the 5-week (by 9.6%) micro-PET imaging sessions. Our results support the notions that FDG PET may be useful in the imaging evaluation of response to androgen ablation therapy and in the early prediction of hormone refractoriness in men with metastatic prostate cancer.

Androgens↗

PubMedDate not supplied

FDG PET in suspected recurrent and metastatic prostate cancer.

Development of an accurate non-invasive imaging technique to detect recurrent and metastatic prostate cancer is critical for the effective management of these patients. The purpose of our study was to determine the diagnostic utility of positron emission tomography with [F-18]fluorodeoxyglucose (FDG PET) in patients with suspected or known metastatic and recurrent prostate cancer. We performed 12 FDG PET scans in 12 men (age 65-81 years) with history of prostate cancer who had previously undergone radical prostatectomy (n=3) or prostate radiotherapy (n=9). Serum prostate specific antigen (PSA) level was elevated in all patients (5-206 ng/ml). Available correlative imaging studies included contrast-enhanced chest, abdomen and pelvis CT (n=8), bone scintigraphy (n=5), and radiography (n=2). PET findings were compared to the findings of the other imaging studies on a lesion-by-lesion basis in individual patients. Validation was by clinical or imaging follow-up for up to 1 year. PET findings were concordant with the findings of the other imaging studies in 7 patients. PET was discordant with the other imaging studies in 5 patients. PET demonstrated suspicious hypermetabolic pelvic lymph nodes in one patient with negative pelvis CT. PET underestimated the extent of osseous metastatic disease in the remaining 4 patients. FDG PET is limited in the detection of osseous metastatic lesions but may be useful in the detection of metastatic nodal and soft tissue disease.

Aged↗